论文部分内容阅读
目的本研究观察硼替佐米联合地塞米松治疗复发/难治多发性骨髓瘤患者的临床疗效与不良反应。方法 11复发/难治多发性骨髓瘤患者应用硼替佐米联合地塞米松治疗。采用欧洲骨髓移植处标准判定疗效,并按WHO标准判定不良反应。结果中位随访9个月,总效率63.7%(7/11),其中完全缓解18.2%(2/11),部分缓解27.3%(3/11),微小反应18.2%(2/11)。主要不良反应有全身周围神经痛,不同程度的血小板减少,感染等,经过对症的调整剂量后均能改善。结论硼替佐米是治疗复发/难治多发性骨髓瘤患者新的有效治疗方案,不良反应轻,安全可靠,患者可耐受。
Objective To observe the clinical efficacy and adverse reactions of bortezomib combined with dexamethasone in patients with relapsed / refractory multiple myeloma. Methods 11 Patients with relapsed / refractory multiple myeloma were treated with bortezomib plus dexamethasone. The European standard of bone marrow transplantation to determine efficacy, and according to WHO criteria to determine adverse reactions. Results The median follow-up was 9 months. The overall response rate was 63.7% (7/11), with complete remission of 18.2% (2/11), partial remission of 27.3% (3/11) and minimal response of 18.2% (2/11). The main adverse reactions are peripheral nerve pain, varying degrees of thrombocytopenia, infection, after symptomatic adjustment of dose can be improved. Conclusion Bortezomib is a new and effective treatment for patients with recurrent / refractory multiple myeloma with mild adverse reactions, safe and reliable, and patients tolerated.